Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Incidence and prognostic value of actionable mutations in early-stage resectable cholangiocarcinoma.
Authors
Kailey Morgan Oppat
Emory University, Atlanta, GA
Kailey Morgan Oppat , Emilie AK Warren , Frances J. Bennett , Amanda Nottke , Hana E. Littleford , Kim M. Phelps , Karen R. Pennington , Ashokkumar A. Patel , Melinda Bachini , Stacie Lindsey , Shishir K. Maithel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 545)
DOI
10.1200/JCO.2024.42.3_suppl.545
Abstract #
545
Poster Bd #
F12
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.
First Author: Ian M. Silverman
Poster
2014 Gastrointestinal Cancers Symposium
Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
First Author: Rachna T. Shroff
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Peri-hilar cholangiocarcinoma (phCCA): A comparative comprehensive genomic profiling study.
First Author: Parth J Sampat
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma.
First Author: Thejus Jayakrishnan